Form 4: IGM Biosciences Director Acquires Stock Options

Julie Hambleton, a director at IGM Biosciences, acquired stock options for 29,400 shares at an exercise price of $9.95 on March 12, 2024.

Summary

• On March 12, 2024, Julie Hambleton, a director of IGM Biosciences, acquired stock options.
• The options grant the right to buy 29,400 shares of IGM Biosciences common stock at an exercise price of $9.95 per share.
• The options vest monthly, with 1/12 of the shares vesting each month following the Issuer's 2024 Annual Meeting of Stockholders, contingent on continued service.
• Full vesting will occur no later than the date of the Issuer's 2025 Annual Meeting of Stockholders.
• The options expire on March 12, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's action suggests confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continued service and the company's annual meetings, suggesting a long-term commitment.

Industry Context

Form 4 filings are routine disclosures of insider transactions and provide transparency to the market regarding the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates